查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
多发性骨髓瘤全球市场规模,份额,行业趋势分析:按最终用户,按疾病(症状性多发性骨髓瘤,冒烟(无症状)多发性骨髓瘤)药物类型,地区展望和预测,2023-2029
市场调查报告书
商品编码
1276458

多发性骨髓瘤全球市场规模,份额,行业趋势分析:按最终用户,按疾病(症状性多发性骨髓瘤,冒烟(无症状)多发性骨髓瘤)药物类型,地区展望和预测,2023-2029

Global Multiple Myeloma Market Size, Share & Industry Trends Analysis Report By End User, By Disease Type (Active Multiple Myeloma and Smoldering Multiple Myeloma), By Drug Type, By Regional Outlook and Forecast, 2023 - 2029
出版日期: | 出版商: KBV Research | 英文 213 Pages | 订单完成后即时交付

价格

多发性骨髓瘤市场规模预计到 2029 年将达到 375 亿美元，预测期内復合年增长率为 9.8%。

多发性骨髓瘤是一个术语，用于描述已发展成恶性肿瘤的浆细胞不受控制的生长。 单克隆免疫球蛋白，或 M 蛋白、M 刺突蛋白和副蛋白，是由浆细胞产生的异常蛋白质（抗体）。 健康的浆细胞产生的免疫球蛋白可有效对抗感染，因为它们可以识别和消除细菌。

然而，癌性浆细胞在多发性骨髓瘤患者的骨髓中积聚并破坏健康的血细胞。 因此，身体会产生一种称为副蛋白的异常蛋白质，它会积聚并损害组织和器官。 多发性骨髓瘤有多种副作用，包括频繁感染、贫血、骨痛和肾臟问题。 治疗选择包括靶向治疗、化学疗法、放射疗法和干细胞移植。

COVID-19 影响分析

由于大流行严重扰乱了研发工作，多发性骨髓瘤的新药和□□治疗方法的开发也被大大推迟。 此外，根据 2021 年 12 月的 Blood Cancer Journal，与 2019 年相比，2020 年新确诊的多发性骨髓瘤病例将减少，这些病例的存活率也在下降。 多发性骨髓瘤患者在 2020 年死亡和感染 COVID-19 的风险增加。 因此，大流行对多发性骨髓瘤市场产生了不利影响。

市场增长因素

全球范围内政府支持计划的增加

在医疗实践的同时，政府和组织还应解决当前与医疗保健提供者关係中出现的其他问题（费用结构和报销、医疗保健设施、药物输送路线、政治和其他网络问题）。正在扩大。 这些问题已通过接受以患者护理为导向的医疗设施得到解决，初级保健医生在这些设施中与专家和其他专家协调护理，并在商业和医疗保险/医疗补助领域建立负担得起的肿瘤中心。我们正在推动实践更多的是付款人和提供者的联合倡议。 因此，预计政府支持的增加将增加对多发性骨髓瘤治疗和药物的需求，从而刺激市场扩张。

全球多发性骨髓瘤病例增加

包括多发性骨髓瘤在内的几种血液系统恶性肿瘤的发病率不断上升，是推动市场发展的关键因素之一。 儘管多发性骨髓瘤被认为是一种罕见的癌症，但全世界有大量癌症患者，这增加了对有效、尖端治疗的需求。 有效的尖端治疗可为患者带来更好的临床结果。 这一点非常重要，因为 MM 的流行在全球呈上升趋势。 此外，研究和开发导致治疗取得进展，需要更复杂的药物来改善结果。

市场製约因素

没有永久的解决办法，许多现有的治疗方法都有副作用

Kyprolis 的常见副作用包括疲劳、低血液和血小板计数、腹泻、便秘、噁心、气短、发烧、四肢肿胀、上呼吸道感染、支气管炎和肺炎。 此外，某些副作用包括低血钾、高血糖、低血钙、肌肉痉挛、四肢麻木或麻痹以及高血压。 放射治疗还会导致疲劳、皮肤刺激、噁心、腹泻、治疗部位脱髮、不育、感染风险增加、食慾不振、后续癌症风险增加以及治疗部位附近器官受损。有副作用比如伤害。

药物类型展望

按药物类型划分，多发性骨髓瘤市场分为化学疗法、蛋白□抑製剂、单克隆抗体等。 2022年，单克隆抗体领域在多发性骨髓瘤市场取得了大幅增长。 随着最近引入的单克隆抗体 (mAb)，多发性骨髓瘤的治疗选择发生了根本性的变化。 elotuzumab 和 daratumumab 在復发/难治性患者中的疗效引起了人们对该疾病的 mAb 的极大兴趣。

最终用户视角

根据最终用户，多发性骨髓瘤市场被细分为医院、诊所等。 2022 年，医院部门在多发性骨髓瘤市场占据了最大的收入份额。 由于患者入院人数增加、多发性骨髓瘤患病率上升以及这些设施拥有合格的医务人员可以改善患者服务等因素，医院部门正在增长。 用于治疗的药物通常在医院开处方和给药，这一事实是该细分市场占据主导地位的重要组成部分。

按疾病类型划分的前景

多发性骨髓瘤市场按疾病类型分为症状性多发性骨髓瘤和冒烟（无症状）多发性骨髓瘤。 在 2022 年的多发性骨髓瘤市场中，冒烟（无症状）多发性骨髓瘤细分市场实现了显着的增长。 该细分市场的增长归因于人们对这种疾病的认识不断提高。 冒烟型（无症状）多发性骨髓瘤可能需要数年才能变得活跃。 因此，一些患有这种综合征的人不会经历有症状的 MM。 医疗保健专业人员通过观察症状转变为症状性多发性骨髓瘤来控制 SMM。

区域展望

按地区分析了北美、欧洲、亚太地区和 LAMEA 的多发性骨髓瘤市场。 到 2022 年，北美部分将在多发性骨髓瘤市场获得最高的收入份额。 由于主要竞争对手的强大存在以及多发性骨髓瘤药物发布和产品批准的增加，预计北美多发性骨髓瘤市场在预测期内将显着扩大。 此外，由于多发性骨髓瘤的患病率上升，市场有望发展。 例如，美国癌症协会预测，到 2023 年，美国将发现 35,730 例多发性骨髓瘤病例。

市场进入者采取的主要策略是收购。 根据基数矩阵中的分析，Novartis AG、Johnson &Johnson、Pfizer, Inc.是多发性骨髓瘤市场的先驱。 Amgen, Inc.、Sanofi S.A. 和 Bristol Myers Squibb Company 等公司是多发性骨髓瘤市场的领先创新者。

内容

第一章市场范围与研究方法

  • 市场定义
  • 目的
  • 市场范围
  • 细分
    • 全球多发性骨髓瘤市场：按最终用户分类
    • 按疾病类型划分的全球多发性骨髓瘤市场
    • 按药物类型划分的全球多发性骨髓瘤市场
    • 全球多发性骨髓瘤市场：按地区
  • 调查方法

第 2 章市场概述

  • 简介
    • 概览
      • 市场构成和情景
  • 影响市场的主要因素
    • 市场驱动因素
    • 市场製约因素

第 3 章竞争分析 - 世界

  • KBV 基数矩阵
  • 近期的全行业战略发展
    • 伙伴关係、协作和协议
    • 产品发布和产品扩展
    • 收购与合併
    • 测试和批准
  • 关键成功策略
    • 主要阅读策略

第 4 章全球多发性骨髓瘤市场：按最终用户分类

  • 全球医院市场：按地区
  • 全球诊所市场：按地区
  • 按地区划分的剩余全球市场

第 5 章全球多发性骨髓瘤市场：按疾病类型分类

  • 全球症状性多发性骨髓瘤市场：按地区
  • 全球冒烟（无症状）多发性骨髓瘤市场：按地区

第 6 章全球多发性骨髓瘤市场：按药物类型分类

  • 全球蛋白□抑製剂市场：按地区
  • 全球单克隆抗体市场：按地区
  • 全球化疗市场：按地区
  • 按地区划分的剩余全球市场

第 7 章。全球多发性骨髓瘤市场：按地区

  • 北美
    • 北美市场：按国家/地区分类
      • 美国
      • 加拿大
      • 墨西哥
      • 其他北美地区
  • 欧洲
    • 欧洲市场：按国家/地区分类
      • 德国
      • 英国
      • 法国
      • 俄罗斯
      • 西班牙
      • 意大利
      • 其他欧洲地区
  • 亚太地区
    • 亚太市场：按国家/地区分类
      • 中国
      • 日本
      • 印度
      • 韩国
      • 新加坡
      • 马来西亚
      • 其他亚太地区
  • 拉丁美洲/中东/非洲
    • 按国家/地区划分的拉丁美洲/中东/非洲市场
      • 巴西
      • 阿根廷
      • 阿拉伯联合酋长国
      • 沙特阿拉伯
      • 南非
      • 尼日利亚
      • 其他拉丁美洲/中东/非洲地区

第八章公司简介

  • Johnson & Johnson
  • Novartis AG
  • Sanofi SA
  • Amgen, Inc
  • AbbVie, Inc
  • Baxter International, Inc
  • Teva Pharmaceutical Industries Ltd
  • Pfizer, Inc
  • Bristol Myers Squibb Company
  • Takeda Pharmaceutical Company Limited

The Global Multiple Myeloma Market size is expected to reach $37.5 billion by 2029, rising at a market growth of 9.8% CAGR during the forecast period.

Multiple myeloma or plasma cell cancer is a disease. The immune system is significantly dependent on healthy plasma cells, which are located in the bone marrow. In order to combat infections and other diseases, the immune system is composed of various cell types. T cells and B cells are two of the most common types of lymphocytes (lymph cells) in the immune system. The lymph nodes, bone marrow, intestines, and circulation are just a few of the organs where lymphocytes can be found.

B cells develop into plasma cells due to the immune system's response to an infection. Antibodies, also known as immunoglobulins, are produced by plasma cells and aid the body's defense against pathogens. Bone marrow contains the majority of plasma cells. Soft tissue found inside bones is called bone marrow. Other blood cells, including red, white, and platelets, are also found in the normal bone marrow and plasma cells.

Multiple myeloma is the term used to describe plasma cells that have developed malignancy and are growing uncontrollably. Monoclonal immunoglobulin, or M-protein, M-spike, or paraprotein, is an aberrant protein (antibody) produced by plasma cells. Immunoglobulins made by healthy plasma cells can recognize and eliminate germs, which is helpful in the fight against infections.

However, cancerous plasma cells gather in the bone marrow of patients with multiple myeloma and destroy healthy blood cells. As a result, the body produces paraproteins, aberrant proteins that can accumulate and harm tissues and organs. Multiple myeloma has several side effects, including frequent infections, anemia, bone pain, and renal problems. Targeted therapy, chemotherapy, radiation therapy, and stem cell transplantation are available as alternatives for treatment.

COVID-19 Impact Analysis

Since R&D operations were substantially hampered by the pandemic, developing novel medicines and treatments for multiple myeloma also slowed considerably. Moreover, the Blood Cancer Journal reported in December 2021 that fewer new instances of multiple myeloma were identified in 2020 in comparison with 2019 and that the survival rate for those cases declined concurrently. Patients with multiple myeloma had a higher mortality rate and COVID-19 infection risk in 2020. Therefore, the pandemic had a detrimental effect on the multiple myeloma market.

Market Growth Factors

Increasing government support initiatives worldwide

Along with care practices, governments and organizations are also extending support for other current problems in provider relations include fee schedules & reimbursement, sites of care, route of drug administration, and politics as well as other network issues. These problems are pushing oncology practices into more payer-provider collaborative initiatives, including accepting patient-care medical homes, where primary care doctors coordinate care with experts and other specialists and creating affordable oncology healthcare institutions in both the commercial and Medicare/Medicaid spaces. Hence, the increasing support of governments is projected to increase demand for treatments or medications for multiple myeloma, thereby fueling market expansion.

Rising cases of multiple myeloma worldwide

The rising incidence of several types of blood malignancies, including multiple myeloma, is one of the major market-driving factors. Although MM is regarded as a more uncommon cancer kind, there are a sizable number of cases of cancer worldwide, and the demand for effective and cutting-edge therapies is rising. Patients frequently experience better and more favorable clinical results when effective and cutting-edge therapies are administered. This is crucial because current trends point to an increase in the prevalence of MM around the globe. In addition, as a result of ongoing R&D, treatment has advanced, necessitating more complex medicines to improve prognosis.

Market Restraining Factors

Lack of permanent solutions and side effects of many existing treatments

Common side effects of Kyprolis include fatigue, a low blood cell count and blood platelet levels, diarrhea, constipation, nausea, shortness of breath, fever, swelling of the extremities, upper respiratory tract infection, bronchitis, and pneumonia. Additionally, certain side effects of the drug include low blood potassium, high blood sugar, low blood calcium, muscle spasms, numbness and tingling in the extremities, and high blood pressure. In addition, radiation therapy can cause adverse effects such as fatigue, irritation of the skin, nausea, diarrhea, loss of hair in the treatment area, infertility, higher risk of infection, loss of appetite, increased risk of subsequent cancer, and harm to organs located near the treatment area.

Drug Type Outlook

Based on drug type, the multiple myeloma market is categorized into chemotherapy, protease inhibitors, monoclonal antibody, and others. The monoclonal antibodies segment procured a considerable growth rate in the multiple myeloma market in 2022. The therapeutic options for multiple myeloma have radically changed due to the recent introduction of monoclonal antibodies (mAbs). The effectiveness of elotuzumab and daratumumab in relapsed/refractory patients has sparked much interest in mAbs for this condition.

End User Outlook

On the basis of end user, the multiple myeloma market is divided into hospitals, clinics, and others. The hospitals segment acquired the largest revenue share in the multiple myeloma market in 2022. The hospital segment is growing due to factors including an increase in patient admissions, a rise in the prevalence of multiple myeloma, and the availability of qualified medical staff in these facilities that enable improved patient services. The fact that the medications used in treatment can be routinely prescribed and given in hospital settings accounts for a significant portion of this segment's dominance.

Disease Type Outlook

Based on disease type, the multiple myeloma market is segmented into active multiple myeloma and smoldering multiple myeloma. The smoldering multiple myeloma segment garnered a remarkable growth rate in the multiple myeloma market in 2022. The growth of the segment is owed to the increasing awareness of the disease. It may take years for smoldering multiple myeloma to develop into an active form. As a result, some individuals with this syndrome never experience active MM. Healthcare professionals' control SMM by watching for symptoms that it's turning into active multiple myeloma.

Regional Outlook

On the basis of region, the multiple myeloma market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment procured the highest revenue share in the multiple myeloma market in 2022. Due to the strong presence of key competitors and the rise in multiple myeloma drug launches and product approvals, the North American multiple myeloma market is predicted to expand considerably over the forecast period. Moreover, the market is anticipated to develop because of the rising prevalence of multiple myeloma. For instance, the American Cancer Society forecasted that by 2023, 35,730 incidences of multiple myeloma would have been discovered in the United States.

The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; Novartis AG, Johnson & Johnson, and Pfizer, Inc. are the forerunners in the Multiple Myeloma Market. Companies such as Amgen, Inc., Sanofi S.A., and Bristol Myers Squibb Company are some of the key innovators in Multiple Myeloma Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Bristol Myers Squibb Company, Amgen, Inc., AbbVie, Inc., Sanofi S.A., Johnson & Johnson, Baxter International, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd., and Pfizer, Inc.

Recent Strategies Deployed in Multiple Myeloma Market

Partnerships, Collaborations and Agreements:

Mar-2022: Sanofi came into collaboration with Blackstone Life Sciences, a US-based private equity firm focused on investing in pharmaceutical, life science, and medical research companies. The collaboration involves the private equity firm contributing up to 300 million euros to advance studies and clinical development programs for the development and delivery of the anti-CD38 antibody Sarclisa focused on treating patients with multiple myeloma.

Jan-2020: Sanofi partnered with Sebia, a France-based provider of clinical protein electrophoresis equipment. The partnership focuses on co-developing treatment for multiple myeloma. The agreement includes, Sebia developing in vitro diagnostic (IVD) tests and acting as its supplier.

Acquisitions and Mergers:

Dec-2022: Johnson & Johnson took over Abiomed, a US-based medical device technology company. The addition of Abiomed advances the acquiring company's MedTech business division, by providing innovational medical technologies. Further, the acquisition broadens Johnson & Johnson's cardiovascular product offerings.

Dec-2021: Baxter acquired Hillrom, a US-based medical device company. The acquisition advances the company's mission to transform healthcare and patient care.

Nov-2021: Pfizer acquired Trillium Therapeutics, a Canada-based clinical-stage immuno-oncology company. The acquisition strengthens the acquiring company's devotion to seeking scientific breakthroughs. Further, the addition of Trillium expands Pfizer's hematology product offerings.

Oct-2021: Amgen completed the acquisition of Teneobio, a US-based biotechnology company. The acquisition of Teneobio broadens the acquiring company's skills and further accelerates its aim to design, build and bring innovations to the markets to better serve their patients. Further, the addition of Teneobio's proprietary bispecific and multispecific antibody technologies perfectly complements Amgen's BiTE platform and its already existing antibody capabilities.

Product Launches and Expansions:

Mar-2023: Teva and Natco together launched extra strengths for the generic version of Revlimid. The medicine is intended to use by adult patients for the cure of multiple myeloma, specific myelodysplastic syndromes, and mantle cell lymphoma. The added strengths reflect the company's devotion to making generic drugs accessible to patients who need them.

Feb-2022: Sandoz, part of Novartis introduced lenalidomide, a generic oncology medicine. The medicine is intended for various haemato-oncology conditions and is available in the form of hard capsules. Lenalidomide is a cost-saving treatment, thereby increasing the treatment's accessibility amongst patients.

Dec-2021: Novartis introduced T-Charge, a CAR-T platform that would act as a base for multiple investigational CAR-T cell therapies. The T-Charge eradicates the need for extended culture time outside the body (ex-vivo), as it primarily happens within a patient's body.

Trials and Approvals:

Oct-2022: The US FDA issued clearance for Johnson & Johnson's Tecvayli, a BCMA-targeted bispecific drug intended for treating patients with refractory or relapsed multiple myeloma. The conditions to be met to use the recently approved drug, patients must have undergone a minimum of four lines of therapy.

Jan-2022: Bristol Myers Squibb received approval for Abecma in Japan. Abecma is a CAR T therapy intended for adult patients with refractory or relapsed (R/R) multiple myeloma. The adult patient should have already received a minimum of three therapies and should have experienced disease progression on the last therapy. Further, the approval demonstrates the company's devotion to catering to the unmet medical needs in Japan.

Dec-2021: U.S. Food and Drug Administration (FDA) approved Amgen's expansion of KYPROLIS to use it in combination with DARZALEX FASPRO, and dexamethasone. The new combination is intended for adult patients with refractory or relapsed multiple myeloma, who have undergone one to three lines of therapy. Further, the combination provides enhanced flexibility and easiness to the patients.

Mar-2020: Sanofi announced FDA approved the use of Sarclisa in combination with dexamethasone and pomalidomide. The combination is intended for the treatment of adults with relapsed refractory multiple myeloma (RRMM), who have already received two therapies. The approval provides patients with hard-to-treat multiple myeloma with a new treatment option.

Scope of the Study

Market Segments covered in the Report:

By End User

  • Hospitals
  • Clinics
  • Others

By Disease Type

  • Active Multiple Myeloma
  • Smoldering Multiple Myeloma

By Drug Type

  • Protease Inhibitors
  • Monoclonal Antibody
  • Chemotherapy
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Novartis AG
  • Bristol Myers Squibb Company
  • Amgen, Inc.
  • AbbVie, Inc.
  • Sanofi S.A.
  • Johnson & Johnson
  • Baxter International, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals Industries Ltd.
  • Pfizer, Inc.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Multiple Myeloma Market, by End User
    • 1.4.2 Global Multiple Myeloma Market, by Disease Type
    • 1.4.3 Global Multiple Myeloma Market, by Drug Type
    • 1.4.4 Global Multiple Myeloma Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition & Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

  • 3.1 KBV Cardinal Matrix
  • 3.2 Recent Industry Wide Strategic Developments
    • 3.2.1 Partnerships, Collaborations and Agreements
    • 3.2.2 Product Launches and Product Expansions
    • 3.2.3 Acquisition and Mergers
    • 3.2.4 Trials and Approvals
  • 3.3 Top Winning Strategies
    • 3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)

Chapter 4. Global Multiple Myeloma Market by End User

  • 4.1 Global Hospitals Market by Region
  • 4.2 Global Clinics Market by Region
  • 4.3 Global Others Market by Region

Chapter 5. Global Multiple Myeloma Market by Disease Type

  • 5.1 Global Active Multiple Myeloma Market by Region
  • 5.2 Global Smoldering Multiple Myeloma Market by Region

Chapter 6. Global Multiple Myeloma Market by Drug Type

  • 6.1 Global Protease Inhibitors Market by Region
  • 6.2 Global Monoclonal Antibody Market by Region
  • 6.3 Global Chemotherapy Market by Region
  • 6.4 Global Others Market by Region

Chapter 7. Global Multiple Myeloma Market by Region

  • 7.1 North America Multiple Myeloma Market
    • 7.1.1 North America Multiple Myeloma Market by End User
      • 7.1.1.1 North America Hospitals Market by Country
      • 7.1.1.2 North America Clinics Market by Country
      • 7.1.1.3 North America Others Market by Country
    • 7.1.2 North America Multiple Myeloma Market by Disease Type
      • 7.1.2.1 North America Active Multiple Myeloma Market by Country
      • 7.1.2.2 North America Smoldering Multiple Myeloma Market by Country
    • 7.1.3 North America Multiple Myeloma Market by Drug Type
      • 7.1.3.1 North America Protease Inhibitors Market by Country
      • 7.1.3.2 North America Monoclonal Antibody Market by Country
      • 7.1.3.3 North America Chemotherapy Market by Country
      • 7.1.3.4 North America Others Market by Country
    • 7.1.4 North America Multiple Myeloma Market by Country
      • 7.1.4.1 US Multiple Myeloma Market
        • 7.1.4.1.1 US Multiple Myeloma Market by End User
        • 7.1.4.1.2 US Multiple Myeloma Market by Disease Type
        • 7.1.4.1.3 US Multiple Myeloma Market by Drug Type
      • 7.1.4.2 Canada Multiple Myeloma Market
        • 7.1.4.2.1 Canada Multiple Myeloma Market by End User
        • 7.1.4.2.2 Canada Multiple Myeloma Market by Disease Type
        • 7.1.4.2.3 Canada Multiple Myeloma Market by Drug Type
      • 7.1.4.3 Mexico Multiple Myeloma Market
        • 7.1.4.3.1 Mexico Multiple Myeloma Market by End User
        • 7.1.4.3.2 Mexico Multiple Myeloma Market by Disease Type
        • 7.1.4.3.3 Mexico Multiple Myeloma Market by Drug Type
      • 7.1.4.4 Rest of North America Multiple Myeloma Market
        • 7.1.4.4.1 Rest of North America Multiple Myeloma Market by End User
        • 7.1.4.4.2 Rest of North America Multiple Myeloma Market by Disease Type
        • 7.1.4.4.3 Rest of North America Multiple Myeloma Market by Drug Type
  • 7.2 Europe Multiple Myeloma Market
    • 7.2.1 Europe Multiple Myeloma Market by End User
      • 7.2.1.1 Europe Hospitals Market by Country
      • 7.2.1.2 Europe Clinics Market by Country
      • 7.2.1.3 Europe Others Market by Country
    • 7.2.2 Europe Multiple Myeloma Market by Disease Type
      • 7.2.2.1 Europe Active Multiple Myeloma Market by Country
      • 7.2.2.2 Europe Smoldering Multiple Myeloma Market by Country
    • 7.2.3 Europe Multiple Myeloma Market by Drug Type
      • 7.2.3.1 Europe Protease Inhibitors Market by Country
      • 7.2.3.2 Europe Monoclonal Antibody Market by Country
      • 7.2.3.3 Europe Chemotherapy Market by Country
      • 7.2.3.4 Europe Others Market by Country
    • 7.2.4 Europe Multiple Myeloma Market by Country
      • 7.2.4.1 Germany Multiple Myeloma Market
        • 7.2.4.1.1 Germany Multiple Myeloma Market by End User
        • 7.2.4.1.2 Germany Multiple Myeloma Market by Disease Type
        • 7.2.4.1.3 Germany Multiple Myeloma Market by Drug Type
      • 7.2.4.2 UK Multiple Myeloma Market
        • 7.2.4.2.1 UK Multiple Myeloma Market by End User
        • 7.2.4.2.2 UK Multiple Myeloma Market by Disease Type
        • 7.2.4.2.3 UK Multiple Myeloma Market by Drug Type
      • 7.2.4.3 France Multiple Myeloma Market
        • 7.2.4.3.1 France Multiple Myeloma Market by End User
        • 7.2.4.3.2 France Multiple Myeloma Market by Disease Type
        • 7.2.4.3.3 France Multiple Myeloma Market by Drug Type
      • 7.2.4.4 Russia Multiple Myeloma Market
        • 7.2.4.4.1 Russia Multiple Myeloma Market by End User
        • 7.2.4.4.2 Russia Multiple Myeloma Market by Disease Type
        • 7.2.4.4.3 Russia Multiple Myeloma Market by Drug Type
      • 7.2.4.5 Spain Multiple Myeloma Market
        • 7.2.4.5.1 Spain Multiple Myeloma Market by End User
        • 7.2.4.5.2 Spain Multiple Myeloma Market by Disease Type
        • 7.2.4.5.3 Spain Multiple Myeloma Market by Drug Type
      • 7.2.4.6 Italy Multiple Myeloma Market
        • 7.2.4.6.1 Italy Multiple Myeloma Market by End User
        • 7.2.4.6.2 Italy Multiple Myeloma Market by Disease Type
        • 7.2.4.6.3 Italy Multiple Myeloma Market by Drug Type
      • 7.2.4.7 Rest of Europe Multiple Myeloma Market
        • 7.2.4.7.1 Rest of Europe Multiple Myeloma Market by End User
        • 7.2.4.7.2 Rest of Europe Multiple Myeloma Market by Disease Type
        • 7.2.4.7.3 Rest of Europe Multiple Myeloma Market by Drug Type
  • 7.3 Asia Pacific Multiple Myeloma Market
    • 7.3.1 Asia Pacific Multiple Myeloma Market by End User
      • 7.3.1.1 Asia Pacific Hospitals Market by Country
      • 7.3.1.2 Asia Pacific Clinics Market by Country
      • 7.3.1.3 Asia Pacific Others Market by Country
    • 7.3.2 Asia Pacific Multiple Myeloma Market by Disease Type
      • 7.3.2.1 Asia Pacific Active Multiple Myeloma Market by Country
      • 7.3.2.2 Asia Pacific Smoldering Multiple Myeloma Market by Country
    • 7.3.3 Asia Pacific Multiple Myeloma Market by Drug Type
      • 7.3.3.1 Asia Pacific Protease Inhibitors Market by Country
      • 7.3.3.2 Asia Pacific Monoclonal Antibody Market by Country
      • 7.3.3.3 Asia Pacific Chemotherapy Market by Country
      • 7.3.3.4 Asia Pacific Others Market by Country
    • 7.3.4 Asia Pacific Multiple Myeloma Market by Country
      • 7.3.4.1 China Multiple Myeloma Market
        • 7.3.4.1.1 China Multiple Myeloma Market by End User
        • 7.3.4.1.2 China Multiple Myeloma Market by Disease Type
        • 7.3.4.1.3 China Multiple Myeloma Market by Drug Type
      • 7.3.4.2 Japan Multiple Myeloma Market
        • 7.3.4.2.1 Japan Multiple Myeloma Market by End User
        • 7.3.4.2.2 Japan Multiple Myeloma Market by Disease Type
        • 7.3.4.2.3 Japan Multiple Myeloma Market by Drug Type
      • 7.3.4.3 India Multiple Myeloma Market
        • 7.3.4.3.1 India Multiple Myeloma Market by End User
        • 7.3.4.3.2 India Multiple Myeloma Market by Disease Type
        • 7.3.4.3.3 India Multiple Myeloma Market by Drug Type
      • 7.3.4.4 South Korea Multiple Myeloma Market
        • 7.3.4.4.1 South Korea Multiple Myeloma Market by End User
        • 7.3.4.4.2 South Korea Multiple Myeloma Market by Disease Type
        • 7.3.4.4.3 South Korea Multiple Myeloma Market by Drug Type
      • 7.3.4.5 Singapore Multiple Myeloma Market
        • 7.3.4.5.1 Singapore Multiple Myeloma Market by End User
        • 7.3.4.5.2 Singapore Multiple Myeloma Market by Disease Type
        • 7.3.4.5.3 Singapore Multiple Myeloma Market by Drug Type
      • 7.3.4.6 Malaysia Multiple Myeloma Market
        • 7.3.4.6.1 Malaysia Multiple Myeloma Market by End User
        • 7.3.4.6.2 Malaysia Multiple Myeloma Market by Disease Type
        • 7.3.4.6.3 Malaysia Multiple Myeloma Market by Drug Type
      • 7.3.4.7 Rest of Asia Pacific Multiple Myeloma Market
        • 7.3.4.7.1 Rest of Asia Pacific Multiple Myeloma Market by End User
        • 7.3.4.7.2 Rest of Asia Pacific Multiple Myeloma Market by Disease Type
        • 7.3.4.7.3 Rest of Asia Pacific Multiple Myeloma Market by Drug Type
  • 7.4 LAMEA Multiple Myeloma Market
    • 7.4.1 LAMEA Multiple Myeloma Market by End User
      • 7.4.1.1 LAMEA Hospitals Market by Country
      • 7.4.1.2 LAMEA Clinics Market by Country
      • 7.4.1.3 LAMEA Others Market by Country
    • 7.4.2 LAMEA Multiple Myeloma Market by Disease Type
      • 7.4.2.1 LAMEA Active Multiple Myeloma Market by Country
      • 7.4.2.2 LAMEA Smoldering Multiple Myeloma Market by Country
    • 7.4.3 LAMEA Multiple Myeloma Market by Drug Type
      • 7.4.3.1 LAMEA Protease Inhibitors Market by Country
      • 7.4.3.2 LAMEA Monoclonal Antibody Market by Country
      • 7.4.3.3 LAMEA Chemotherapy Market by Country
      • 7.4.3.4 LAMEA Others Market by Country
    • 7.4.4 LAMEA Multiple Myeloma Market by Country
      • 7.4.4.1 Brazil Multiple Myeloma Market
        • 7.4.4.1.1 Brazil Multiple Myeloma Market by End User
        • 7.4.4.1.2 Brazil Multiple Myeloma Market by Disease Type
        • 7.4.4.1.3 Brazil Multiple Myeloma Market by Drug Type
      • 7.4.4.2 Argentina Multiple Myeloma Market
        • 7.4.4.2.1 Argentina Multiple Myeloma Market by End User
        • 7.4.4.2.2 Argentina Multiple Myeloma Market by Disease Type
        • 7.4.4.2.3 Argentina Multiple Myeloma Market by Drug Type
      • 7.4.4.3 UAE Multiple Myeloma Market
        • 7.4.4.3.1 UAE Multiple Myeloma Market by End User
        • 7.4.4.3.2 UAE Multiple Myeloma Market by Disease Type
        • 7.4.4.3.3 UAE Multiple Myeloma Market by Drug Type
      • 7.4.4.4 Saudi Arabia Multiple Myeloma Market
        • 7.4.4.4.1 Saudi Arabia Multiple Myeloma Market by End User
        • 7.4.4.4.2 Saudi Arabia Multiple Myeloma Market by Disease Type
        • 7.4.4.4.3 Saudi Arabia Multiple Myeloma Market by Drug Type
      • 7.4.4.5 South Africa Multiple Myeloma Market
        • 7.4.4.5.1 South Africa Multiple Myeloma Market by End User
        • 7.4.4.5.2 South Africa Multiple Myeloma Market by Disease Type
        • 7.4.4.5.3 South Africa Multiple Myeloma Market by Drug Type
      • 7.4.4.6 Nigeria Multiple Myeloma Market
        • 7.4.4.6.1 Nigeria Multiple Myeloma Market by End User
        • 7.4.4.6.2 Nigeria Multiple Myeloma Market by Disease Type
        • 7.4.4.6.3 Nigeria Multiple Myeloma Market by Drug Type
      • 7.4.4.7 Rest of LAMEA Multiple Myeloma Market
        • 7.4.4.7.1 Rest of LAMEA Multiple Myeloma Market by End User
        • 7.4.4.7.2 Rest of LAMEA Multiple Myeloma Market by Disease Type
        • 7.4.4.7.3 Rest of LAMEA Multiple Myeloma Market by Drug Type

Chapter 8. Company Profiles

  • 8.1 Johnson & Johnson
    • 8.1.1 Company Overview
    • 8.1.2 Financial Analysis
    • 8.1.3 Segmental &Regional Analysis
    • 8.1.4 Research & Development Expenses
    • 8.1.5 Recent strategies and developments:
      • 8.1.5.1 Trials and Approvals:
      • 8.1.5.2 Acquisition and Mergers:
    • 8.1.6 SWOT Analysis
  • 8.2 Novartis AG
    • 8.2.1 Company Overview
    • 8.2.2 Financial Analysis
    • 8.2.3 Segmental and Regional Analysis
    • 8.2.4 Research & Development Expense
    • 8.2.5 Recent strategies and developments:
      • 8.2.5.1 Partnerships, Collaborations, and Agreements:
      • 8.2.5.2 Product Launches and Product Expansions:
  • 8.3 Sanofi S.A.
    • 8.3.1 Company Overview
    • 8.3.2 Financial Analysis
    • 8.3.3 Segmental and Regional Analysis
    • 8.3.4 Research & Development Expense
    • 8.3.5 Recent strategies and developments:
      • 8.3.5.1 Partnerships, Collaborations, and Agreements:
      • 8.3.5.2 Trials and Approvals:
  • 8.4 Amgen, Inc.
    • 8.4.1 Company Overview
    • 8.4.2 Financial Analysis
    • 8.4.3 Regional Analysis
    • 8.4.4 Research & Development Expenses
    • 8.4.5 Recent strategies and developments:
      • 8.4.5.1 Trials and Approvals:
      • 8.4.5.2 Acquisition and Mergers:
  • 8.5 AbbVie, Inc.
    • 8.5.1 Company Overview
    • 8.5.2 Financial Analysis
    • 8.5.3 Regional Analysis
    • 8.5.4 Research & Development Expense
    • 8.5.5 Recent strategies and developments:
      • 8.5.5.1 Partnerships, Collaborations, and Agreements:
  • 8.6 Baxter International, Inc.
    • 8.6.1 Company Overview
    • 8.6.2 Financial Analysis
    • 8.6.3 Segmental and Regional Analysis
    • 8.6.4 Research & Development Expense
    • 8.6.5 Recent strategies and developments:
      • 8.6.5.1 Acquisition and Mergers:
  • 8.7 Teva Pharmaceutical Industries Ltd.
    • 8.7.1 Company Overview
    • 8.7.2 Financial Analysis
    • 8.7.3 Regional Analysis
    • 8.7.4 Research & Development Expenses
    • 8.7.5 Recent strategies and developments:
      • 8.7.5.1 Product Launches and Product Expansions:
  • 8.8 Pfizer, Inc.
    • 8.8.1 Company Overview
    • 8.8.2 Financial Analysis
    • 8.8.3 Regional & Segmental Analysis
    • 8.8.4 Research & Development Expense
    • 8.8.5 Recent strategies and developments:
      • 8.8.5.1 Acquisition and Mergers:
  • 8.9 Bristol Myers Squibb Company
    • 8.9.1 Company Overview
    • 8.9.2 Financial Analysis
    • 8.9.3 Regional Analysis
    • 8.9.4 Research & Development Expenses
    • 8.9.5 Recent strategies and developments:
      • 8.9.5.1 Trials and Approvals:
      • 8.9.5.2 Acquisition and Mergers:
  • 8.10. Takeda Pharmaceutical Company Limited
    • 8.10.1 Company Overview
    • 8.10.2 Financial Analysis
    • 8.10.3 Regional Analysis
    • 8.10.4 Research & Development Expense

LIST OF TABLES

  • TABLE 1 Global Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 2 Global Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 3 Partnerships, Collaborations and Agreements- Multiple Myeloma Market
  • TABLE 4 Product Launches And Product Expansions- Multiple Myeloma Market
  • TABLE 5 Acquisition and Mergers- Multiple Myeloma Market
  • TABLE 6 Trials and approvals - Multiple Myeloma Market
  • TABLE 7 Global Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 8 Global Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 9 Global Hospitals Market by Region, 2019 - 2022, USD Million
  • TABLE 10 Global Hospitals Market by Region, 2023 - 2029, USD Million
  • TABLE 11 Global Clinics Market by Region, 2019 - 2022, USD Million
  • TABLE 12 Global Clinics Market by Region, 2023 - 2029, USD Million
  • TABLE 13 Global Others Market by Region, 2019 - 2022, USD Million
  • TABLE 14 Global Others Market by Region, 2023 - 2029, USD Million
  • TABLE 15 Global Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 16 Global Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 17 Global Active Multiple Myeloma Market by Region, 2019 - 2022, USD Million
  • TABLE 18 Global Active Multiple Myeloma Market by Region, 2023 - 2029, USD Million
  • TABLE 19 Global Smoldering Multiple Myeloma Market by Region, 2019 - 2022, USD Million
  • TABLE 20 Global Smoldering Multiple Myeloma Market by Region, 2023 - 2029, USD Million
  • TABLE 21 Global Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 22 Global Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 23 Global Protease Inhibitors Market by Region, 2019 - 2022, USD Million
  • TABLE 24 Global Protease Inhibitors Market by Region, 2023 - 2029, USD Million
  • TABLE 25 Global Monoclonal Antibody Market by Region, 2019 - 2022, USD Million
  • TABLE 26 Global Monoclonal Antibody Market by Region, 2023 - 2029, USD Million
  • TABLE 27 Global Chemotherapy Market by Region, 2019 - 2022, USD Million
  • TABLE 28 Global Chemotherapy Market by Region, 2023 - 2029, USD Million
  • TABLE 29 Global Others Market by Region, 2019 - 2022, USD Million
  • TABLE 30 Global Others Market by Region, 2023 - 2029, USD Million
  • TABLE 31 Global Multiple Myeloma Market by Region, 2019 - 2022, USD Million
  • TABLE 32 Global Multiple Myeloma Market by Region, 2023 - 2029, USD Million
  • TABLE 33 North America Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 34 North America Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 35 North America Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 36 North America Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 37 North America Hospitals Market by Country, 2019 - 2022, USD Million
  • TABLE 38 North America Hospitals Market by Country, 2023 - 2029, USD Million
  • TABLE 39 North America Clinics Market by Country, 2019 - 2022, USD Million
  • TABLE 40 North America Clinics Market by Country, 2023 - 2029, USD Million
  • TABLE 41 North America Others Market by Country, 2019 - 2022, USD Million
  • TABLE 42 North America Others Market by Country, 2023 - 2029, USD Million
  • TABLE 43 North America Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 44 North America Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 45 North America Active Multiple Myeloma Market by Country, 2019 - 2022, USD Million
  • TABLE 46 North America Active Multiple Myeloma Market by Country, 2023 - 2029, USD Million
  • TABLE 47 North America Smoldering Multiple Myeloma Market by Country, 2019 - 2022, USD Million
  • TABLE 48 North America Smoldering Multiple Myeloma Market by Country, 2023 - 2029, USD Million
  • TABLE 49 North America Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 50 North America Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 51 North America Protease Inhibitors Market by Country, 2019 - 2022, USD Million
  • TABLE 52 North America Protease Inhibitors Market by Country, 2023 - 2029, USD Million
  • TABLE 53 North America Monoclonal Antibody Market by Country, 2019 - 2022, USD Million
  • TABLE 54 North America Monoclonal Antibody Market by Country, 2023 - 2029, USD Million
  • TABLE 55 North America Chemotherapy Market by Country, 2019 - 2022, USD Million
  • TABLE 56 North America Chemotherapy Market by Country, 2023 - 2029, USD Million
  • TABLE 57 North America Others Market by Country, 2019 - 2022, USD Million
  • TABLE 58 North America Others Market by Country, 2023 - 2029, USD Million
  • TABLE 59 North America Multiple Myeloma Market by Country, 2019 - 2022, USD Million
  • TABLE 60 North America Multiple Myeloma Market by Country, 2023 - 2029, USD Million
  • TABLE 61 US Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 62 US Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 63 US Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 64 US Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 65 US Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 66 US Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 67 US Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 68 US Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 69 Canada Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 70 Canada Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 71 Canada Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 72 Canada Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 73 Canada Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 74 Canada Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 75 Canada Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 76 Canada Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 77 Mexico Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 78 Mexico Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 79 Mexico Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 80 Mexico Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 81 Mexico Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 82 Mexico Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 83 Mexico Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 84 Mexico Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 85 Rest of North America Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 86 Rest of North America Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 87 Rest of North America Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 88 Rest of North America Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 89 Rest of North America Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 90 Rest of North America Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 91 Rest of North America Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 92 Rest of North America Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 93 Europe Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 94 Europe Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 95 Europe Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 96 Europe Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 97 Europe Hospitals Market by Country, 2019 - 2022, USD Million
  • TABLE 98 Europe Hospitals Market by Country, 2023 - 2029, USD Million
  • TABLE 99 Europe Clinics Market by Country, 2019 - 2022, USD Million
  • TABLE 100 Europe Clinics Market by Country, 2023 - 2029, USD Million
  • TABLE 101 Europe Others Market by Country, 2019 - 2022, USD Million
  • TABLE 102 Europe Others Market by Country, 2023 - 2029, USD Million
  • TABLE 103 Europe Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 104 Europe Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 105 Europe Active Multiple Myeloma Market by Country, 2019 - 2022, USD Million
  • TABLE 106 Europe Active Multiple Myeloma Market by Country, 2023 - 2029, USD Million
  • TABLE 107 Europe Smoldering Multiple Myeloma Market by Country, 2019 - 2022, USD Million
  • TABLE 108 Europe Smoldering Multiple Myeloma Market by Country, 2023 - 2029, USD Million
  • TABLE 109 Europe Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 110 Europe Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 111 Europe Protease Inhibitors Market by Country, 2019 - 2022, USD Million
  • TABLE 112 Europe Protease Inhibitors Market by Country, 2023 - 2029, USD Million
  • TABLE 113 Europe Monoclonal Antibody Market by Country, 2019 - 2022, USD Million
  • TABLE 114 Europe Monoclonal Antibody Market by Country, 2023 - 2029, USD Million
  • TABLE 115 Europe Chemotherapy Market by Country, 2019 - 2022, USD Million
  • TABLE 116 Europe Chemotherapy Market by Country, 2023 - 2029, USD Million
  • TABLE 117 Europe Others Market by Country, 2019 - 2022, USD Million
  • TABLE 118 Europe Others Market by Country, 2023 - 2029, USD Million
  • TABLE 119 Europe Multiple Myeloma Market by Country, 2019 - 2022, USD Million
  • TABLE 120 Europe Multiple Myeloma Market by Country, 2023 - 2029, USD Million
  • TABLE 121 Germany Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 122 Germany Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 123 Germany Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 124 Germany Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 125 Germany Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 126 Germany Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 127 Germany Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 128 Germany Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 129 UK Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 130 UK Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 131 UK Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 132 UK Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 133 UK Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 134 UK Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 135 UK Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 136 UK Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 137 France Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 138 France Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 139 France Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 140 France Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 141 France Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 142 France Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 143 France Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 144 France Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 145 Russia Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 146 Russia Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 147 Russia Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 148 Russia Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 149 Russia Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 150 Russia Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 151 Russia Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 152 Russia Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 153 Spain Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 154 Spain Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 155 Spain Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 156 Spain Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 157 Spain Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 158 Spain Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 159 Spain Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 160 Spain Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 161 Italy Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 162 Italy Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 163 Italy Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 164 Italy Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 165 Italy Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 166 Italy Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 167 Italy Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 168 Italy Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 169 Rest of Europe Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 170 Rest of Europe Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 171 Rest of Europe Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 172 Rest of Europe Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 173 Rest of Europe Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 174 Rest of Europe Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 175 Rest of Europe Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 176 Rest of Europe Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 177 Asia Pacific Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 178 Asia Pacific Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 179 Asia Pacific Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 180 Asia Pacific Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 181 Asia Pacific Hospitals Market by Country, 2019 - 2022, USD Million
  • TABLE 182 Asia Pacific Hospitals Market by Country, 2023 - 2029, USD Million
  • TABLE 183 Asia Pacific Clinics Market by Country, 2019 - 2022, USD Million
  • TABLE 184 Asia Pacific Clinics Market by Country, 2023 - 2029, USD Million
  • TABLE 185 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
  • TABLE 186 Asia Pacific Others Market by Country, 2023 - 2029, USD Million
  • TABLE 187 Asia Pacific Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 188 Asia Pacific Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 189 Asia Pacific Active Multiple Myeloma Market by Country, 2019 - 2022, USD Million
  • TABLE 190 Asia Pacific Active Multiple Myeloma Market by Country, 2023 - 2029, USD Million
  • TABLE 191 Asia Pacific Smoldering Multiple Myeloma Market by Country, 2019 - 2022, USD Million
  • TABLE 192 Asia Pacific Smoldering Multiple Myeloma Market by Country, 2023 - 2029, USD Million
  • TABLE 193 Asia Pacific Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 194 Asia Pacific Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 195 Asia Pacific Protease Inhibitors Market by Country, 2019 - 2022, USD Million
  • TABLE 196 Asia Pacific Protease Inhibitors Market by Country, 2023 - 2029, USD Million
  • TABLE 197 Asia Pacific Monoclonal Antibody Market by Country, 2019 - 2022, USD Million
  • TABLE 198 Asia Pacific Monoclonal Antibody Market by Country, 2023 - 2029, USD Million
  • TABLE 199 Asia Pacific Chemotherapy Market by Country, 2019 - 2022, USD Million
  • TABLE 200 Asia Pacific Chemotherapy Market by Country, 2023 - 2029, USD Million
  • TABLE 201 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
  • TABLE 202 Asia Pacific Others Market by Country, 2023 - 2029, USD Million
  • TABLE 203 Asia Pacific Multiple Myeloma Market by Country, 2019 - 2022, USD Million
  • TABLE 204 Asia Pacific Multiple Myeloma Market by Country, 2023 - 2029, USD Million
  • TABLE 205 China Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 206 China Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 207 China Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 208 China Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 209 China Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 210 China Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 211 China Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 212 China Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 213 Japan Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 214 Japan Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 215 Japan Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 216 Japan Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 217 Japan Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 218 Japan Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 219 Japan Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 220 Japan Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 221 India Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 222 India Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 223 India Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 224 India Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 225 India Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 226 India Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 227 India Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 228 India Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 229 South Korea Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 230 South Korea Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 231 South Korea Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 232 South Korea Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 233 South Korea Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 234 South Korea Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 235 South Korea Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 236 South Korea Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 237 Singapore Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 238 Singapore Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 239 Singapore Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 240 Singapore Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 241 Singapore Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 242 Singapore Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 243 Singapore Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 244 Singapore Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 245 Malaysia Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 246 Malaysia Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 247 Malaysia Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 248 Malaysia Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 249 Malaysia Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 250 Malaysia Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 251 Malaysia Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 252 Malaysia Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 253 Rest of Asia Pacific Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 254 Rest of Asia Pacific Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 255 Rest of Asia Pacific Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 256 Rest of Asia Pacific Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 257 Rest of Asia Pacific Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 258 Rest of Asia Pacific Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 259 Rest of Asia Pacific Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 260 Rest of Asia Pacific Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 261 LAMEA Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 262 LAMEA Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 263 LAMEA Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 264 LAMEA Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 265 LAMEA Hospitals Market by Country, 2019 - 2022, USD Million
  • TABLE 266 LAMEA Hospitals Market by Country, 2023 - 2029, USD Million
  • TABLE 267 LAMEA Clinics Market by Country, 2019 - 2022, USD Million
  • TABLE 268 LAMEA Clinics Market by Country, 2023 - 2029, USD Million
  • TABLE 269 LAMEA Others Market by Country, 2019 - 2022, USD Million
  • TABLE 270 LAMEA Others Market by Country, 2023 - 2029, USD Million
  • TABLE 271 LAMEA Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 272 LAMEA Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 273 LAMEA Active Multiple Myeloma Market by Country, 2019 - 2022, USD Million
  • TABLE 274 LAMEA Active Multiple Myeloma Market by Country, 2023 - 2029, USD Million
  • TABLE 275 LAMEA Smoldering Multiple Myeloma Market by Country, 2019 - 2022, USD Million
  • TABLE 276 LAMEA Smoldering Multiple Myeloma Market by Country, 2023 - 2029, USD Million
  • TABLE 277 LAMEA Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 278 LAMEA Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 279 LAMEA Protease Inhibitors Market by Country, 2019 - 2022, USD Million
  • TABLE 280 LAMEA Protease Inhibitors Market by Country, 2023 - 2029, USD Million
  • TABLE 281 LAMEA Monoclonal Antibody Market by Country, 2019 - 2022, USD Million
  • TABLE 282 LAMEA Monoclonal Antibody Market by Country, 2023 - 2029, USD Million
  • TABLE 283 LAMEA Chemotherapy Market by Country, 2019 - 2022, USD Million
  • TABLE 284 LAMEA Chemotherapy Market by Country, 2023 - 2029, USD Million
  • TABLE 285 LAMEA Others Market by Country, 2019 - 2022, USD Million
  • TABLE 286 LAMEA Others Market by Country, 2023 - 2029, USD Million
  • TABLE 287 LAMEA Multiple Myeloma Market by Country, 2019 - 2022, USD Million
  • TABLE 288 LAMEA Multiple Myeloma Market by Country, 2023 - 2029, USD Million
  • TABLE 289 Brazil Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 290 Brazil Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 291 Brazil Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 292 Brazil Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 293 Brazil Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 294 Brazil Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 295 Brazil Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 296 Brazil Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 297 Argentina Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 298 Argentina Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 299 Argentina Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 300 Argentina Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 301 Argentina Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 302 Argentina Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 303 Argentina Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 304 Argentina Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 305 UAE Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 306 UAE Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 307 UAE Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 308 UAE Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 309 UAE Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 310 UAE Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 311 UAE Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 312 UAE Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 313 Saudi Arabia Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 314 Saudi Arabia Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 315 Saudi Arabia Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 316 Saudi Arabia Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 317 Saudi Arabia Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 318 Saudi Arabia Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 319 Saudi Arabia Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 320 Saudi Arabia Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 321 South Africa Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 322 South Africa Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 323 South Africa Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 324 South Africa Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 325 South Africa Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 326 South Africa Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 327 South Africa Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 328 South Africa Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 329 Nigeria Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 330 Nigeria Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 331 Nigeria Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 332 Nigeria Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 333 Nigeria Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 334 Nigeria Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 335 Nigeria Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 336 Nigeria Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 337 Rest of LAMEA Multiple Myeloma Market, 2019 - 2022, USD Million
  • TABLE 338 Rest of LAMEA Multiple Myeloma Market, 2023 - 2029, USD Million
  • TABLE 339 Rest of LAMEA Multiple Myeloma Market by End User, 2019 - 2022, USD Million
  • TABLE 340 Rest of LAMEA Multiple Myeloma Market by End User, 2023 - 2029, USD Million
  • TABLE 341 Rest of LAMEA Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
  • TABLE 342 Rest of LAMEA Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
  • TABLE 343 Rest of LAMEA Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
  • TABLE 344 Rest of LAMEA Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
  • TABLE 345 Key information -Johnson & Johnson
  • TABLE 346 Key Information - Novartis AG
  • TABLE 347 Key Information - Sanofi S.A.
  • TABLE 348 Key Information - Amgen, Inc.
  • TABLE 349 Key information - AbbVie, Inc.
  • TABLE 350 Key Information - Baxter International, Inc.
  • TABLE 351 Key Information - Teva Pharmaceuticals Industries Ltd.
  • TABLE 352 Key Information - Pfizer, Inc.
  • TABLE 353 Key Information - Bristol Myers Squibb Company
  • TABLE 354 Key Information - Takeda Pharmaceutical Company Limited

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 KBV Cardinal Matrix
  • FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
  • FIG 4 Global Multiple Myeloma Market share by End User, 2022
  • FIG 5 Global Multiple Myeloma Market share by End User, 2029
  • FIG 6 Global Multiple Myeloma Market by End User, 2019 - 2029, USD Million
  • FIG 7 Global Multiple Myeloma Market share by Disease Type, 2022
  • FIG 8 Global Multiple Myeloma Market share by Disease Type, 2029
  • FIG 9 Global Multiple Myeloma Market by Disease Type, 2019 - 2029, USD Million
  • FIG 10 Global Multiple Myeloma Market share by Drug Type, 2022
  • FIG 11 Global Multiple Myeloma Market share by Drug Type, 2029
  • FIG 12 Global Multiple Myeloma Market by Drug Type, 2019 - 2029, USD Million
  • FIG 13 Global Multiple Myeloma Market share by Region, 2022
  • FIG 14 Global Multiple Myeloma Market share by Region, 2029
  • FIG 15 Global Multiple Myeloma Market by Region, 2019 - 2029, USD Million
  • FIG 16 SWOT analysis: Johnson & Johnson
  • FIG 17 Recent strategies and developments: Novartis AG
  • FIG 18 Recent strategies and developments: Sanofi S.A.